METTL3 and breast cancer: Collectively, the experimental data of our study demonstrated that silencing METTL3 reduced the drug resistance of BC cells to ADR, and promoted cancer cell apoptosis by downregulating miR-221-3p expression through inhibition of the m6A modification of pri-miR-221-3p.